Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may cut unnecessary lung cancer scans in High-Risk groups

NCT ID NCT07358715

Diagnosis Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test (liquid biopsy) can be used as a first step to screen for lung cancer in high-risk people, before deciding if they need a low-dose CT scan. The goal is to reduce unnecessary scans, radiation exposure, and healthcare costs. The study will enroll 140 participants, including smokers and never-smokers with a family history of lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liquid biopsy (SPOT-MAS assay and exosome-based assay)
What this could lead to
If successful, this blood test could help avoid unnecessary CT scans and radiation exposure for many people at high risk for lung cancer, making screening more efficient and affordable.
What could go wrong
This is a small, early feasibility study (140 participants). The blood test may not be accurate enough to replace CT scans, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria High-Risk Individuals (n = 100) * No prior history of lung cancer * Meets one of the following high-risk definitions: * Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR * Never-smoker aged 55-75 years with a first-degree family history of lung cancer * Able and willing to provide written informed consent Early-Stage Lung Cancer Patients (n = 20) * Aged ≥21 years * Histologically or clinically confirmed stage I-II lung cancer * Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer) * Able and willing to provide written informed consent Advanced-Stage Lung Cancer Patients (n = 20) * Aged ≥21 years * Histologically or clinically confirmed stage III-IV lung cancer * Treatment-naïve (no prior systemic or local therapy for lung cancer) * Able and willing to provide written informed consent Exclusion Criteria Applicable to All Participants * Pregnant or breastfeeding women * Inability or unwillingness to comply with study procedures High-Risk Individuals Only * Known allergy or contraindication to CT contrast agents * Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment Lung Cancer Cohorts Only • Receipt of any prior cancer-directed treatment for lung cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer screening Early lung cancer detection High-risk populations Lung cancer Lung neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National University Hospital Singapore

    RECRUITING

    Singapore, 119228, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.